Concise Analysis of New Methods for Treating Refractory Hematological Malignancies – Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
DUBLIN, Mar. 26, 2014 /PRNewswire/ –
Research and Markets
) has announced the addition of the
report to their offering.
Targeting unmet needs in the treatment of cancer through innovative drug development strategies have witnessed favourable outcomes recently. New targets have been validated in this process where kinases lead the way. The success has boosted the innovative biotech sector and is reflected in the performance of the IPOs’ since 2010 till date. Positive clinical data/ regulatory approval, lucrative partnership/ acquisition announcement have increased the confidence of investors on innovation and whetted their appetite for risk associated with innovation!
Several companies that have recently made their debut in public (NASDAQ) are addressing unmet needs/ niche indications with novel technology platforms/targets. Earlier, the authors had highlighted the investment opportunity and drugs being developed for Relapsed and Refractory Multiple Myeloma (RRMM). Approval of Kyprolis (carfilzomib, Onyx), Pomalyst (pomalidomide, Celgene) for this indication and their successful commercial launch validate the strategy deployed by the companies. They expect a similar scenario to unfold in the treatment of recurrent/ refractory MDS (RR-MDS, High-Risk MDS), and AML (relapsed/ refractory AML, R/R AML) and in this report highlight the new drugs and companies developing these drugs.
Key Topics Covered:
1. Executive Summary
2. Investment Drivers of The Select Companies Covered
3. Myelodysplastic syndrome (MDS)
4. Acute Myelogenous Leukemia (AML)
5. Competitive Landscape: RR/ High-Risk MDS and RR AML
6. Competitive Landscape: Untreated/ Newly Diagnosed MDS and AML
7. Key Milestones
8. Launch Timeline and Commercial Opportunity of Late-stage Pipeline (RR MDS and RR AML)
9. Drivers of M&A / Licensing Deals in MDS/ AML
10.1 Ambit Biosciences (AMBI)
-- AC 220 -- BI 6727 -- C-kit positive -- CPX-351 -- Celgene -- Elderly AML -- Estybon -- FLT3 mutation -- IPSS-R -- Quizartinib -- R/R AML -- Sapacitabine -- Sunesis -- SymBio -- Vidaza -- Volasertib -- Vosaroxin -- azacitidine -- decitabine -- high risk -- higher risk -- intermediate-1 -- intermediate-2 -- kinase -- lower risk -- lower risk -- newly diagnosed -- older AML -- refractory -- relapsed -- rigosertib -- stem cell transplantation
For more information visit http://www.researchandmarkets.com/research/pt8tl4/treating
Laura Wood , +353-1-481-1716, firstname.lastname@example.org
SOURCE Research and Markets